Shanghai - Delayed Quote CNY

Harbin Pharmaceutical Group Co., Ltd. (600664.SS)

3.7800
+0.0400
+(1.07%)
At close: May 23 at 3:00:03 PM GMT+8
Loading Chart for 600664.SS
  • Previous Close 3.7400
  • Open 3.7300
  • Bid 3.7700 x --
  • Ask 3.7800 x --
  • Day's Range 3.7200 - 3.8600
  • 52 Week Range 2.5400 - 4.9700
  • Volume 86,426,051
  • Avg. Volume 55,171,959
  • Market Cap (intraday) 9.52B
  • Beta (5Y Monthly) 0.19
  • PE Ratio (TTM) 14.54
  • EPS (TTM) 0.2600
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 4, 2018
  • 1y Target Est --

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium iron zinc oral solutions, zinc gluconate oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, recombinant human erythropoietin injections, ibuprofen granules, iron vitamin B12 oral solutions, ceftriaxone sodium injections, pediatric acetaminophen granules, Jiananxi Vitapak nutrition packages, lacidipine tablets, roxatidine acetate hydrochloride for injections, and penicillin and cephalosporin antibiotic preparations. The company sells its products under the Harbin Pharmaceutical, Sanjing, Gaizhonggai, Hutong, and Shiyitang brands. It is also involved in culture, science and technology, passenger transport, food, property, security, and pharmaceutical investment services, as well as biology and health technology activities. Harbin Pharmaceutical Group Co., Ltd. was founded in 1991 and is based in Harbin, China.

www.hayao.com

10,180

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600664.SS

View More

Performance Overview: 600664.SS

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600664.SS
8.47%
SSE Composite Index (000001.SS)
0.10%

1-Year Return

600664.SS
27.27%
SSE Composite Index (000001.SS)
7.44%

3-Year Return

600664.SS
26.85%
SSE Composite Index (000001.SS)
6.40%

5-Year Return

600664.SS
9.88%
SSE Composite Index (000001.SS)
19.00%

Compare To: 600664.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600664.SS

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    9.52B

  • Enterprise Value

    8.07B

  • Trailing P/E

    14.54

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.59

  • Price/Book (mrq)

    1.71

  • Enterprise Value/Revenue

    0.50

  • Enterprise Value/EBITDA

    8.42

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.10%

  • Return on Assets (ttm)

    3.86%

  • Return on Equity (ttm)

    12.06%

  • Revenue (ttm)

    16.21B

  • Net Income Avi to Common (ttm)

    665.03M

  • Diluted EPS (ttm)

    0.2600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.8B

  • Total Debt/Equity (mrq)

    21.48%

  • Levered Free Cash Flow (ttm)

    572.5M

Research Analysis: 600664.SS

View More

Company Insights: 600664.SS

Research Reports: 600664.SS

View More

People Also Watch